{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:37:49Z","timestamp":1788341869131,"version":"build-2803163510"},"reference-count":171,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2020,8,23]],"date-time":"2020-08-23T00:00:00Z","timestamp":1598140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP18H02946"],"award-info":[{"award-number":["JP18H02946"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Endometrial cancer (EC) is one of the most common malignancies of the female reproductive organs. The most characteristic feature of EC is the frequent association with metabolic disorders. However, the components of these disorders that are involved in carcinogenesis remain unclear. Accumulating epidemiological studies have clearly revealed that hyperinsulinemia, which accompanies these disorders, plays central roles in the development of EC via the insulin-phosphoinositide 3 kinase (PI3K) signaling pathway as a metabolic driver. Recent comprehensive genomic analyses showed that over 90% of ECs have genomic alterations in this pathway, resulting in enhanced insulin signaling and production of optimal tumor microenvironments (TMEs). Targeting PI3K signaling is therefore an attractive treatment strategy. Several clinical trials for recurrent or advanced ECs have been attempted using PI3K-serine\/threonine kinase (AKT) inhibitors. However, these agents exhibited far lower efficacy than expected, possibly due to activation of alternative pathways that compensate for the PIK3-AKT pathway and allow tumor growth, or due to adaptive mechanisms including the insulin feedback pathway that limits the efficacy of agents. Overcoming these responses with careful management of insulin levels is key to successful treatment. Further interest in specific TMEs via the insulin PI3K-pathway in obese women will provide insight into not only novel therapeutic strategies but also preventive strategies against EC.<\/jats:p>","DOI":"10.3390\/ijms21176073","type":"journal-article","created":{"date-parts":[[2020,8,23]],"date-time":"2020-08-23T21:28:06Z","timestamp":1598218086000},"page":"6073","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Endometrial Cancer as a Metabolic Disease with Dysregulated PI3K Signaling: Shedding Light on Novel Therapeutic Strategies"],"prefix":"10.3390","volume":"21","author":[{"given":"Satoru","family":"Kyo","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane 693-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane 693-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,8,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.2217\/fon.14.192","article-title":"USA endometrial cancer projections to 2030: Should we be concerned?","volume":"10","author":"Sheikh","year":"2014","journal-title":"Future Oncol."},{"key":"ref_3","unstructured":"Cancer Information Service (2016). Cancer Registry and Statistics (Vital Statistics of Japan)."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJM199608293350907","article-title":"Endometrial carcinoma","volume":"335","author":"Rose","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(15)00130-0","article-title":"Endometrial cancer","volume":"387","author":"Morice","year":"2016","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ajog.2007.08.075","article-title":"Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths","volume":"198","author":"Ueda","year":"2008","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","article-title":"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers","volume":"94","author":"Hamilton","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ygyno.2012.09.012","article-title":"Uterine papillary serous cancer: A review of the literature","volume":"127","author":"Birrer","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/GRF.0b013e318218c6d1","article-title":"Recurrent endometrial cancer","volume":"54","author":"Boruta","year":"2011","journal-title":"Clin. Obstet. Gynecol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network, Kandoth, C., Schultz, N., Cherniack, A.D., Akbani, R., Liu, Y., Shen, H., Robertson, A.G., Pashtan, I., and Shen, R. (2013). Integrated genomic characterization of endometrial carcinoma. Nature, 497, 67\u201373.","DOI":"10.1038\/nature12113"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/PAS.0b013e31827f576a","article-title":"Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma","volume":"37","author":"Gilks","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/modpathol.2013.102","article-title":"Reproducibility of histological cell type in high-grade endometrial carcinoma","volume":"26","author":"Han","year":"2013","journal-title":"Mod. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2014.05.006","article-title":"POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium","volume":"134","author":"Meng","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/modpathol.2015.43","article-title":"Refining prognosis and identifying targetable pathways for high-risk endometrial cancer: A TransPORTEC initiative","volume":"28","author":"Stelloo","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/cncr.29046","article-title":"Polymerase \u025b (POLE) mutations in endometrial cancer: Clinical outcomes and implications for Lynch syndrome testing","volume":"12","author":"Billingsley","year":"2015","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_18","first-page":"402","article-title":"Prognostic significance of POLE proofreading mutations in endometrial cancer","volume":"107","author":"Church","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network, Weinstein, J.N., Collisson, E.A., Mills, G.B., Shaw, K.R., Ozenberger, B.A., Ellrott, K., Shmulevich, I., Sander, C., and Stuart, J.M. (2013). The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet., 45, 1113\u20131120.","DOI":"10.1038\/ng.2764"},{"key":"ref_21","first-page":"5248","article-title":"A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer","volume":"58","author":"Boland","year":"1998","journal-title":"Cancer Res."},{"key":"ref_22","first-page":"5100","article-title":"Genetic instability of microsatellites in endometrial carcinoma","volume":"53","author":"Risinger","year":"1993","journal-title":"Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1038\/sj.onc.1206365","article-title":"Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers","volume":"22","author":"Kanaya","year":"2003","journal-title":"Oncogene"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/0092-8674(93)90546-3","article-title":"The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer","volume":"75","author":"Fishel","year":"1993","journal-title":"Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1038\/sj.onc.1202178","article-title":"MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas","volume":"17","author":"Esteller","year":"1998","journal-title":"Oncogene"},{"key":"ref_26","first-page":"3607","article-title":"Methylation of hMLH1 in a population-based series of endometrial carcinomas","volume":"6","author":"Salvesen","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1158\/1078-0432.CCR-15-0057","article-title":"POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer","volume":"21","author":"Eggink","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.18632\/oncotarget.23790","article-title":"Microsatellite instability is a Biomark. for immune checkpoint inhibitors in endometrial cancer","volume":"9","author":"Yamashita","year":"2017","journal-title":"Oncotarget"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/jjco\/hyy159","article-title":"Molecular-targeted therapies and precision medicine for endometrial cancer","volume":"49","author":"Mitamura","year":"2019","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_30","first-page":"628","article-title":"Decision making in precision oncology: An issue of mutational contextuality","volume":"9","author":"Dey","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"ref_31","first-page":"963","article-title":"Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas","volume":"10","author":"Sherman","year":"1997","journal-title":"Mod. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1677\/ERC-07-0132","article-title":"Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC)","volume":"14","author":"Cust","year":"2007","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/aje\/kwq006","article-title":"Metabolic syndrome and endometrial carcinoma","volume":"171","author":"Stocks","year":"2010","journal-title":"Am. J. Epidemiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ygyno.2009.12.029","article-title":"The association between metabolic abnormality and endometrial cancer: A large case-control study in China","volume":"117","author":"Zhang","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1158\/1055-9965.EPI-11-0715","article-title":"Case-control study of the metabolic syndrome and metabolic risk factors for endometrial cancer","volume":"20","author":"Friedenreich","year":"2011","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/annonc\/mdq464","article-title":"Metabolic syndrome and endometrial cancer risk","volume":"22","author":"Rosato","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1158\/1055-9965.EPI-14-0923","article-title":"Metabolic syndrome and risk of endometrial cancer in the united states: A study in the SEER-medicare linked database","volume":"24","author":"Trabert","year":"2015","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s12020-013-9973-3","article-title":"Metabolic syndrome and endometrial cancer: A meta-analysis","volume":"45","author":"Esposito","year":"2014","journal-title":"Endocrine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(08)60269-X","article-title":"Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies","volume":"371","author":"Renehan","year":"2008","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ygyno.2013.11.012","article-title":"Bariatric surgery decreases the risk of uterine malignancy","volume":"133","author":"Ward","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00125-007-0681-5","article-title":"Diabetes mellitus and risk of endometrial cancer: A meta-analysis","volume":"50","author":"Friberg","year":"2007","journal-title":"Diabetologia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ygyno.2014.07.095","article-title":"Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies","volume":"135","author":"Liao","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ygyno.2019.09.014","article-title":"A prospective clinical cohort study of women at increased risk for endometrial cancer","volume":"156","author":"Clarke","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1158\/1055-9965.EPI-18-1031","article-title":"Genome-Wide Association Studies of Endometrial Cancer: Latest Developments and Future Directions","volume":"28","author":"Glubb","year":"2019","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1093\/hmg\/ddu328","article-title":"Mendelian randomization: Genetic anchors for causal inference in epidemiological studies","volume":"23","author":"Hemani","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Prescott, J., Setiawan, V.W., Wentzensen, N., Schumacher, F., Yu, H., Delahanty, R., Bernstein, L., Chanock, S.J., Chen, C., and Cook, L.S. (2015). Body Mass Index Genetic Risk Score and Endometrial Cancer Risk. PLoS ONE., 10.","DOI":"10.1371\/journal.pone.0143256"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1158\/1055-9965.EPI-16-0147","article-title":"Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer","volume":"25","author":"Painter","year":"2016","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/0002-9378(79)90289-8","article-title":"Effects of long-term estrogen replacement therapy. II. Neoplasia","volume":"133","author":"Hammond","year":"1979","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0921-4410(04)22023-3","article-title":"Systemic therapy for gynecological neoplasms: Ovary, cervix, and endometrium","volume":"22","author":"Pecorelli","year":"2005","journal-title":"Cancer Chemother. Biol. Response Modif."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"R125","DOI":"10.1530\/ERC-14-0580","article-title":"Body fatness as a cause of cancer: Epidemiologic clues to biologic mechanisms","volume":"22","author":"Byers","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1055\/s-2007-1016244","article-title":"Aromatase in aging women","volume":"17","author":"Bulun","year":"1999","journal-title":"Semin. Reprod. Endocrinol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0960-0760(99)00048-5","article-title":"Intratumoral levels of estrogens in breast cancer","volume":"69","author":"Blankenstein","year":"1999","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1530\/ERC-15-0386","article-title":"CYP19A1 fine-mapping and Mendelian randomization: Estradiol is causal for endometrial cancer","volume":"23","author":"Thompson","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/ng.3841","article-title":"Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk","volume":"49","author":"Day","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/MED.0b013e328353732f","article-title":"Evolving utility of sex hormone-binding globulin measurements in clinical medicine","volume":"19","author":"Hammond","year":"2012","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1210\/jc.2004-0762","article-title":"Sex hormone-binding globulin and insulin-like growth factor-binding protein-1 as indicators of metabolic syndrome, cardiovascular risk, and mortality in elderly men","volume":"90","author":"Kalme","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1753-4887.2008.00083.x","article-title":"Impact of diet and adiposity on circulating levels of sex hormone-binding globulin and androgens","volume":"66","author":"Morisset","year":"2008","journal-title":"Nutr. Rev."},{"key":"ref_58","first-page":"3979","article-title":"Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone-binding globulin gene. Version 2","volume":"117","author":"Selva","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/ni.2343","article-title":"Immunological complications of obesity","volume":"13","author":"Kanneganti","year":"2012","journal-title":"Nat. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1210\/me.2007-0529","article-title":"Adipokines and the peripheral and neural control of energy balance","volume":"22","author":"Ahima","year":"2008","journal-title":"Mol. Endocrinol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"E466","DOI":"10.1152\/ajpendo.00266.2012","article-title":"Inflammation during obesity is not all bad: Evidence from animal and human studies","volume":"304","author":"Ye","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11684-013-0262-6","article-title":"Mechanisms of insulin resistance in obesity","volume":"7","author":"Ye","year":"2013","journal-title":"Front. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3389\/fonc.2019.00744","article-title":"The Role of Metabolic Syndrome in Endometrial Cancer: A Review","volume":"9","author":"Yang","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fcvm.2020.00022","article-title":"Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease","volume":"7","author":"Chait","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1123\/pes.24.3.461","article-title":"Adipocytokine levels in children: Effects of fatness and training","volume":"24","author":"Aggeloussi","year":"2012","journal-title":"Pediatr. Exerc. Sci."},{"key":"ref_66","first-page":"594","article-title":"Serum adiponectin in relation to endometrial cancer and endometrial hyperplasia with atypia in obese women","volume":"29","author":"Bedner","year":"2008","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1159\/000430327","article-title":"Adiponectin and Endometrial Cancer: A Systematic Review and Meta-Analysis","volume":"36","author":"Zeng","year":"2015","journal-title":"Cell Physiol. Biochem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1158\/1535-7163.MCT-11-0545","article-title":"Direct role of adiponectin and adiponectin receptors in endometrial cancer: In vitro and ex vivo studies in humans","volume":"10","author":"Moon","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ygyno.2020.05.033","article-title":"Adipocytokines and their relationship to endometrial cancer risk: A systematic review and meta-analysis","volume":"158","author":"Ellis","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"a009191","DOI":"10.1101\/cshperspect.a009191","article-title":"Insulin receptor signaling in normal and insulin-resistant states","volume":"6","author":"Boucher","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fendo.2013.00071","article-title":"Adipokines mediate inflammation and insulin resistance","volume":"4","author":"Kwon","year":"2013","journal-title":"Front. Endocrinol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"35375","DOI":"10.1074\/jbc.M806480200","article-title":"S6K directly phosphorylates IRS-1 on Ser-270 to promote insulin resistance in response to TNF-(alpha) signaling through IKK2","volume":"283","author":"Zhang","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"26602","DOI":"10.1074\/jbc.M601284200","article-title":"Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance","volume":"281","author":"Kamei","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature01137","article-title":"A central role for JNK in obesity and insulin resistance","volume":"420","author":"Hirosumi","year":"2002","journal-title":"Nature"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"45777","DOI":"10.1074\/jbc.M301977200","article-title":"Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects","volume":"278","author":"Rotter","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1210\/en.2006-0692","article-title":"Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression","volume":"148","author":"Jager","year":"2007","journal-title":"Endocrinology"},{"key":"ref_77","first-page":"1723","article-title":"Insulin-like growth factor system gene expression in human endometrium during the menstrual cycle","volume":"79","author":"Zhou","year":"1994","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_78","first-page":"3227","article-title":"Portal insulin concentrations rather than insulin sensitivity regulate serum sex hormone-binding globulin and insulin-like growth factor binding protein 1 in vivo","volume":"80","author":"Utriainen","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.3390\/jcm3041561","article-title":"The Insulin-Like Growth Factor System in Obesity, Insulin Resistance and Type 2 Diabetes Mellitus","volume":"3","author":"Lewitt","year":"2014","journal-title":"J. Clin. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/humrep\/15.suppl_3.173","article-title":"Insulin-like growth factors and insulin-like growth factor binding proteins in the endometrium. Effect of intrauterine levonorgestrel delivery","volume":"15","author":"Rutanen","year":"2000","journal-title":"Hum. Reprod."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1507\/endocrj.44.419","article-title":"Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer","volume":"44","author":"Ayabe","year":"1997","journal-title":"Endocr. J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-06-0912","article-title":"Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium","volume":"12","author":"McCampbell","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.ejca.2011.09.014","article-title":"p53 Regulates insulin-like growth factor-I receptor gene expression in uterine serous carcinoma and predicts responsiveness to an insulin-like growth factor-I receptor-directed targeted therapy","volume":"48","author":"Bentov","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/IGC.0b013e318254011f","article-title":"BRCA1 is expressed in uterine serous carcinoma (USC) and controls insulin-like growth factor I receptor (IGF-IR) gene expression in USC cell lines","volume":"22","author":"Amichay","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1210\/endo.135.6.7527333","article-title":"Expression of insulin-like growth factors and their binding proteins in the estrogen responsive Ishikawa human endometrial cancer cell line","volume":"135","author":"Hana","year":"1994","journal-title":"Endocrinology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1210\/endo.136.6.7750475","article-title":"Modulation of insulin-like growth factor I (IGF-I) receptors and membrane-associated IGF-binding proteins in endometrial cancer cells by estradiol","volume":"136","author":"Kleinman","year":"1995","journal-title":"Endocrinology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jdiacomp.2010.06.004","article-title":"Substantially increased risk of cancer in patients with diabetes mellitus: A systematic review and meta-analysis of epidemiologic evidence in Japan","volume":"24","author":"Noto","year":"2010","journal-title":"J. Diabetes Its Complicat."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/IGC.0b013e31827b8430","article-title":"The Role of Preexisting Diabetes Mellitus on Incidence and Mortality of Endometrial Cancer: A Meta-Analysis of Prospective Cohort Studies","volume":"23","author":"Zhang","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1001\/jama.2008.824","article-title":"Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: A systematic review and meta-analysis","volume":"300","author":"Barone","year":"2008","journal-title":"JAMA"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1038\/sj.bjc.6604313","article-title":"Body mass, diabetes and smoking, and endometrial cancer risk: A follow-up study","volume":"98","author":"Lindemann","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/sj.bjc.6603933","article-title":"Diabetes and endometrial cancer: Effect modification by body weight, physical activity and hypertension","volume":"97","author":"Lucenteforte","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_92","first-page":"611","article-title":"Diabetes and endometrial cancer in the Iowa women\u2019s health study","volume":"10","author":"Anderson","year":"2001","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/bjc.2014.407","article-title":"Association between diabetes, diabetes treatment and risk of developing endometrial cancer","volume":"111","author":"Luo","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/ijc.10974","article-title":"Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort","volume":"104","author":"Furberg","year":"2003","journal-title":"Int. J. Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/1055-9965.EPI-07-2686","article-title":"A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer","volume":"17","author":"Gunter","year":"2008","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s10552-011-9794-8","article-title":"Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer","volume":"22","author":"Lambe","year":"2011","journal-title":"Cancer Causes Control"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2337\/dc06-0922","article-title":"Prospective study of hyperglycemia and cancer risk","volume":"30","author":"Stattin","year":"2007","journal-title":"Diabetes Care"},{"key":"ref_98","first-page":"128","article-title":"Association between endometrial cancer and metabolic syndrome","volume":"45","author":"Shou","year":"2010","journal-title":"Chin. J. Obstet. Gynecol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1530\/ERC-12-0211","article-title":"Case-control study of markers of insulin resistance and endometrial cancer risk","volume":"19","author":"Friedenreich","year":"2012","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ygyno.2011.11.013","article-title":"Morbidly obese women with and without endometrial cancer: Are there differences in measured physical fitness, body composition, or hormones?","volume":"124","author":"Modesitt","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ijc.27622","article-title":"Serum insulin-like, growth factor binding protein-related protein 1 (IGFBP-rP1) and endometrial cancer risk in Chinese women","volume":"132","author":"Zhan","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3109\/09513590.2015.1058355","article-title":"Relation of metabolic syndrome with endometrial pathologies in patients with abnormal uterine bleeding","volume":"31","author":"Batmaz","year":"2015","journal-title":"Gynecol. Endocrinol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"djv178","DOI":"10.1093\/jnci\/djv178","article-title":"Evidence of a Causal Association Between Insulinemia and Endometrial Cancer: A Mendelian Randomization Analysis","volume":"107","author":"Nead","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ceb.2017.02.007","article-title":"PI3K signaling in cancer: Beyond AKT","volume":"45","author":"Lien","year":"2017","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccr.2009.04.012","article-title":"AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer","volume":"16","author":"Vasudevan","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrg1879","article-title":"The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism","volume":"7","author":"Engelman","year":"2006","journal-title":"Nat. Rev. Genet."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41574-020-0329-9","article-title":"Insulin-PI3K signaling: An evolutionarily insulated metabolic driver of cancer","volume":"16","author":"Hopkins","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1126\/science.1139952","article-title":"Quantitative mass spectrometry identifies insulin signaling targets in C. elegans","volume":"317","author":"Dong","year":"2007","journal-title":"Science"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K Pathway in Human Disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cell.2015.12.042","article-title":"Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton","volume":"164","author":"Hu","year":"2016","journal-title":"Cell"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.124.3215.269","article-title":"On respiratory impairment in cancer cells","volume":"124","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.cell.2008.08.021","article-title":"Cancer cell metabolism: Warburg and beyond","volume":"134","author":"Hsu","year":"2008","journal-title":"Cell"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: The metabolic requirements of cell proliferation","volume":"324","author":"Cantley","year":"2009","journal-title":"Science"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11892-012-0356-6","article-title":"The links between insulin resistance, diabetes, and cancer","volume":"13","author":"Orgel","year":"2013","journal-title":"Curr. Diab. Rep."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1158\/0008-5472.CAN-09-2141","article-title":"Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes","volume":"70","author":"Novosyadlyy","year":"2010","journal-title":"Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.ygyno.2012.03.012","article-title":"Mitogenic and anti-apoptotic effects of insulin in endometrial cancer are phosphatidylinositol 3-kinase\/Akt dependent","volume":"125","author":"Wang","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1126\/science.1120781","article-title":"The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin","volume":"310","author":"Shaw","year":"2005","journal-title":"Science"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nature07782","article-title":"Tumours with PI3K activation are resistant to dietary restriction","volume":"458","author":"Kalaany","year":"2009","journal-title":"Nature"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3389\/fonc.2018.00341","article-title":"Metformin as a Therapeutic Target in Endometrial Cancers","volume":"8","author":"Lee","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1158\/0008-5472.CAN-07-2310","article-title":"Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells","volume":"67","author":"Dowling","year":"2007","journal-title":"Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"221","DOI":"10.7314\/APJCP.2015.16.1.221","article-title":"Metformin down-regulates endometrial carcinoma cell secretion of IGF-1 and expression of IGF-1R","volume":"16","author":"Zhang","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Sarfstein, R., Friedman, Y., Attias-Geva, Z., Fishman, A., Bruchim, I., and Werner, H. (2013). Metformin downregulates the insulin\/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners. PLoS ONE., 8.","DOI":"10.1371\/journal.pone.0061537"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.3892\/ol.2014.2466","article-title":"Regulation of insulin-like growth factor signaling by metformin in endometrial cancer cells","volume":"8","author":"Xie","year":"2014","journal-title":"Oncol. Lett."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/cas.13083","article-title":"Metformin inhibits estrogen-dependent endometrial cancer cell growth by activating the AMPK-FOXO1 signal pathway","volume":"107","author":"Zou","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ygyno.2013.10.026","article-title":"Metformin use and endometrial cancer survival","volume":"132","author":"Nevadunsky","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ygyno.2013.11.021","article-title":"Metformin is associated with improved survival in endometrial cancer","volume":"132","author":"Ko","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"419","DOI":"10.17772\/gp\/2397","article-title":"Do endometrial cancer patients benefit from metformin intake","volume":"86","author":"Zaborowski","year":"2015","journal-title":"Ginekol. Pol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ygyno.2015.11.019","article-title":"The effect of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts","volume":"140","author":"Mariani","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Ezewuiro, O., Grushko, T.A., Kocherginsky, M., Habis, M., Hurteau, J.A., Mills, K.A., Hunn, J., Olopade, O.I., Fleming, G.F., and Romero, I.L. (2016). Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy. PLoS ONE., 11.","DOI":"10.1371\/journal.pone.0147145"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ejogrb.2016.06.013","article-title":"The prognostic role of metformin in patients with endometrial cancer: A retrospective study","volume":"203","author":"Seebacher","year":"2016","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ygyno.2017.07.120","article-title":"Effects of metformin on endometrial cancer: Systematic review and meta-analysis","volume":"147","author":"Meireles","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1002\/cncr.28853","article-title":"Effects of metformin on endometrial cancer cell growth in vivo: A preoperative prospective trial","volume":"120","author":"Mitsuhashi","year":"2014","journal-title":"Cancer"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"10067","DOI":"10.7314\/APJCP.2014.15.23.10067","article-title":"Antiproliferative effect of metformin on the endometrium\u2014A clinical trial","volume":"15","author":"Tabrizi","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"173","DOI":"10.7150\/jca.8009","article-title":"Combination of Diane-35 and Metformin to Treat Early Endometrial Carcinoma in PCOS Women with Insulin Resistance","volume":"5","author":"Li","year":"2014","journal-title":"J. Cancer"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ygyno.2014.06.014","article-title":"Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer","volume":"134","author":"Laskov","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/cam4.353","article-title":"Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer","volume":"4","author":"Schuler","year":"2015","journal-title":"Cancer Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1097\/IGC.0000000000000818","article-title":"Insulin-Like Growth Factor 1\/Mammalian Target of Rapamycin and AMP-Activated Protein Kinase Signaling Involved in the Effects of Metformin in the Human Endometrial Cancer","volume":"26","author":"Cai","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/bjc.2015.453","article-title":"Measuring the biological effect of presurgical metformin treatment in endometrial cancer","volume":"114","author":"Sivalingam","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ygyno.2016.10.011","article-title":"Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study","volume":"143","author":"Soliman","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/annonc\/mdv539","article-title":"Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer","volume":"27","author":"Mitsuhashi","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/09513590.2017.1409714","article-title":"Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K\/AKT\/mTOR signaling","volume":"34","author":"Zhao","year":"2018","journal-title":"Gynecol. Endocrinol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1158\/1078-0432.CCR-18-3339","article-title":"PRE-surgical Metformin In Uterine Malignancy (PREMIUM): A Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial","volume":"25","author":"Kitson","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"733","DOI":"10.31557\/APJCP.2020.21.3.733","article-title":"Effect of Metformin for decreasing proliferative marker in women with endometrial cancer: A randomized double-blind placebo-controlled trial","volume":"21","author":"Petchsila","year":"2020","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/1471-0528.16108","article-title":"Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: A randomised controlled trial","volume":"127","author":"Yang","year":"2020","journal-title":"BJOG"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1002\/cncr.25515","article-title":"A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma","volume":"116","author":"Slomovitz","year":"2010","journal-title":"Cancer"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1200\/JCO.2010.34.1578","article-title":"Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: A trial of the NCIC Clinical Trials Group","volume":"29","author":"Oza","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/bjc.2013.183","article-title":"Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORA.D., a phase II trial of GINECO","volume":"108","author":"Favier","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/bjc.2013.59","article-title":"Ridaforolimus as a single agent in advanced endometrial cancer: Results of a single-arm, phase 2 trial","volume":"108","author":"Colombo","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ygyno.2014.06.033","article-title":"Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer","volume":"135","author":"Tsoref","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ygyno.2014.01.015","article-title":"Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: A gynecologic oncology group study","volume":"132","author":"Fleming","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.2014.58.8871","article-title":"Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma","volume":"33","author":"Oza","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ygyno.2015.12.025","article-title":"Temsirolimus in women with platinum-refractory\/resistant ovarian cancer or advanced\/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8)","volume":"140","author":"Emons","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ygyno.2016.04.019","article-title":"A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer","volume":"142","author":"Birrer","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1158\/1078-0432.CCR-17-2260","article-title":"A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers","volume":"24","author":"Banerji","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/ijc.32783","article-title":"Phase, I.I., 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer","volume":"147","author":"Myers","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1158\/1078-0432.CCR-17-3440","article-title":"The Strategy of PIKing a Target: What Is AKTually Most Effective?","volume":"24","author":"Costa","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ccell.2014.11.007","article-title":"Measurement of PIP3 levels reveals an unexpected role for p110\u03b2 in early adaptive responses to p110\u03b1-specific inhibitors in luminal breast cancer","volume":"27","author":"Costa","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1002\/jcp.25850","article-title":"The SGK1 inhibitor SI113 induces autophagy, apoptosis, and endoplasmic reticulum stress in endometrial cancer cells","volume":"232","author":"Conza","year":"2017","journal-title":"J. Cell Physiol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41586-018-0343-4","article-title":"Suppression of insulin feedback enhances the efficacy of PI3K inhibitors","volume":"560","author":"Hopkins","year":"2018","journal-title":"Nature"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1158\/1535-7163.MCT-14-0330","article-title":"Suppression of feedback loops mediated by PI3K\/mTOR induces multiple overactivation of compensatory pathways: An unintended consequence leading to drug resistance","volume":"13","author":"Rozengurt","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1038\/onc.2011.495","article-title":"Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia","volume":"31","author":"Gallagher","year":"2012","journal-title":"Oncogene"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1158\/1078-0432.CCR-14-2518","article-title":"Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade","volume":"21","author":"Iams","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1158\/1535-7163.MCT-10-0318","article-title":"Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): Rationale for cotargeting IGF-1R and IR in cancer","volume":"9","author":"Buck","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1210\/en.2013-2032","article-title":"Effects of the antitumor drug OSI-906, a dual inhibitor of IGF-1 receptor and insulin receptor, on the glycemic control, \u03b2-cell functions, and \u03b2-cell proliferation in male mice","volume":"155","author":"Shirakawa","year":"2014","journal-title":"Endocrinology"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40170-019-0203-1","article-title":"SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia","volume":"7","author":"Nasiri","year":"2019","journal-title":"Cancer Metab."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1210\/jc.2018-01147","article-title":"High-Dose, Diazoxide-Mediated Insulin Suppression Boosts Weight Loss Induced by Lifestyle Intervention","volume":"103","author":"Loves","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1210\/jc.2018-00161","article-title":"Effects of Diazoxide-Mediated Insulin Suppression on Glucose and Lipid Metabolism in Nondiabetic Obese Men","volume":"103","author":"Loves","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1056\/NEJMra1704560","article-title":"Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer","volume":"379","author":"Goncalves","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/aje\/kwy249","article-title":"Associations of a Healthy Lifestyle Index With the Risks of Endometrial and Ovarian Cancer Among Women in the Women\u2019s Health Initiative Study","volume":"188","author":"Arthur","year":"2019","journal-title":"Am. J. Epidemiol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/17\/6073\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:05:30Z","timestamp":1760177130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/17\/6073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,23]]},"references-count":171,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["ijms21176073"],"URL":"https:\/\/doi.org\/10.3390\/ijms21176073","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,23]]}}}